Immunocompatible chorionic membrane products

Patent metadata

Field	Value
Publication number	US-11590172-B2
Application number	US-201916296463-A
Country	US
Kind code	B2
Filing date	Mar 8, 2019
Priority date	Feb 18, 2010
Publication date	Feb 28, 2023
Grant date	Feb 28, 2023

Abstract

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

First claim

What is claimed is:

1. A cryopreserved chorionic membrane comprising native therapeutic cells and matrix metalloproteinase-9 (MMP-9), wherein at least 70% of the native therapeutic cells in the chorionic membrane are viable, wherein the viable native therapeutic cells comprise one or more of mesenchymal stem cells (MSCs), stromal cells, and fibroblast cells, and wherein the cryopreserved chorionic membrane is substantially free of CD14+ macrophage cells.

2. The cryopreserved chorionic membrane of claim 1 , comprising: a cryopreserving amount of a cryopreservative; wherein the cryopreserved chorionic membrane comprises a reticular layer and a stromal layer that both comprise viable therapeutic cells, and wherein the cryopreserved chorionic membrane is substantially free of vascularized tissue or vascularized tissue derived immunogenic cells.

3. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane is substantially free of trophoblasts.

4. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane comprises insulin-like growth factor binding protein-1 and adiponectin.

5. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane has been disinfected.

6. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane has a square shape.

7. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane does not include an amniotic membrane.

8. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane has a thickness of 40 to 400 micrometers.

9. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane is substantially free of vascularized tissue or vascularized tissue-derived immunogenic cells.

10. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane comprises CD14+ macrophages in an amount of less than 5% of the amount of CD14+ macrophage cells in an unprocessed chorionic membrane.

11. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane has a width×length dimension of 5 centimeters by 5 centimeters.

Assignees

• Osiris Therapeutics Inc

Inventors

• Tom Samson
• Danilkovitch Alla
• Yoo Dana
• Jansen Timothy
• Kuang Jin-Qiang
• Marconi Jennifer Michelle

Classifications

• A01N1/125 Primary

  Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators · CPC title

• C12N2500/02

  Atmosphere, e.g. low oxygen conditions · CPC title

• C12N2502/025

  extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K38/1825

  Fibroblast growth factor [FGF] · CPC title